icon-folder.gif   Conference Reports for NATAP  
  EACS - 12th European AIDS Conference
November 11-14, 2009
Cologne, Germany
Back grey_arrow_rt.gif
Absence of a teratogenic potential from a novel
next-generation NNRTI, TMC278

  Reported by Jules Levin
EACS Nov 13 Cologne Germany
M Desmidt,1 B Willems,1 P Dom,1 G Bailey,1 L De Schaepdrijver,1 L Lammens,1 S Lachau-Durand,2 F van Velsen,2 M Martens,2 W Coussement1 1Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium; 2Tibotec BVBA, Mechelen, Belgium
TMC278 did not show teratogenic potential in rat and rabbit models at exposures 13- to 80-times higher than those seen in HIV-1-infected patients receiving 25mg qd TMC278 at steady-state
- AUC0-24h: 2.8µg·h/mL (Phase IIb TMC278-C204 study)
- AUC0- ∞: 37µg·h/mL (NOAEL 40mg/kg/day pregnant rats and foetuses)
- AUC0-24h: 170-232µg·h/mL (NOAEL 10mg/kg/day rabbit foetuses and 20mg/kg/day pregnant rabbits).
These animal data suggest that further studies of TMC278 in WOCBP are warranted.



TMC278 (rilpivirine) is an investigational next-generation NNRTI that has very good anti-HIV-1 activity and a favourable safety/tolerability profile at a convenient once-daily dose of 25mg. The embryo-foetal toxicity of TMC278 was investigated in rats and rabbits.
TMC278 was administered by oral gavage at doses of up to 400mg/kg/day to pregnant Sprague-Dawley rats and up to 20mg/kg/day in pregnant New Zealand white rabbits during the period of organogenesis (gestation Days 6-17 in rats and Days 6-19 in rabbits).
In rats, at the 120mg/kg/day and 400mg/kg/day doses, indications of moderate maternal toxicity were noted (reduced food consumption and bodyweight gain, and increased thyroid weight). In rabbits, there was no maternal toxicity up to 20mg/kg/day. In rats and rabbits, no teratogenic effect was seen. There was no effect of treatment on pregnancy parameters in any group. The only finding on embryo-foetal development in rats was a slight increase in the incidence of a visceral variant, dilated renal pelvis, at the 120mg/kg/day and 400mg/kg/day doses. The maternal and embryo-foetal no observable adverse effect level (NOAEL) was 40mg/kg/day, associated with a maternal area under the plasma concentration-time curve from time of administration to 24 hours after dosing (AUC0-24h) value of 37µg·h/mL. The only finding on embryo-foetal development in rabbits was a slight increase in the incidence of foetuses exhibiting minor variations of the left subclavian artery originating from the aorta and of hypoplastic interparietal bone in the group given 20mg/kg/day. The maternal toxicity and embryo-foetal NOAELs were 20mg/kg/day and 10mg/kg/day, respectively, associated with maternal AUC0-24h values of 232µg·h/mL and 170µg·h/mL. The mean AUC0-24h value in HIV-1-infected patients at 25mg TMC278 qd was 2.8µg·h/mL.
The absence of a teratogenic potential from TMC278 in the rat and rabbit models even at exposures many times higher than those in the clinic is a key element in its safety profile.















1. Molina J-M, et al. HIV9 2008. Abstract P002.